Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.
The optimal method for measuring cancer extent in prostate biopsy specimens is unknown. Seven hundred forty-four patients diagnosed between 1990 and 1996 with prostate cancer and managed conservatively were identified. The clinical end point was death from prostate cancer. The extent of cancer was measured in terms of number of cancer cores (NCC), percentage of cores with cancer (PCC), total length of cancer (LCC) and percentage length of cancer in the cores (PLC). These were correlated with prostate cancer mortality, in univariate and multivariate analysis including Gleason score and prostate-specific antigen (PSA). All extent of cancer variables were significant predictors of prostate cancer death on univariate analysis: NCC, hazard ration (HR) = 1.15, 95% confidence interval (CI) = 1.04-1.28, P = 0.011; PPC, HR = 1.01, 95% CI = 1.01-1.02, P < 0.0001; LCC, HR = 1.02, 95% CI = 1.01-1.03, P = 0.002; PLC, HR = 1.01, 95% CI = 1.01-1.02, P = 0.0001. In multivariate analysis including Gleason score and baseline PSA, PCC and PLC were both independently significant P = 0.004 and P = 0.012, respectively, and added further information to that provided by PSA and Gleason score, whereas NNC and LCC were no longer significant (P = 0.5 and P = 0.3 respectively). In a final model, including both extent of cancer variables, PCC was the stronger, adding more value than PLC (χ² (1df) = 7.8, P = 0.005, χ² (1df) = 0.5, P = 0.48 respectively). Measurements of disease burden in needle biopsy specimens are significant predictors of prostate-cancer-related death. The percentage of positive cores appeared the strongest predictor and was stronger than percentage length of cancer in the cores.
Rajab
Ramzi
R
Centre for Molecular Oncology and Imaging, Queen Mary University of London, UK.
Fisher
Gabrielle
G
Kattan
Michael W
MW
Foster
Christopher S
CS
Oliver
Tim
T
Møller
Henrik
H
Reuter
Victor
V
Scardino
Peter
P
Cuzick
Jack
J
Berney
Daniel M
DM
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D001707:Biopsy, Needle; D015331:Cohort Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D010340:Pathology, Surgical / Q000379:methods* / Q000592:standards; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery
D017430:Prostate-Specific Antigen
J Urol. 2004 Jun;171(6 Pt 1):2215-20
15126788
Urology. 2002 Sep;60(3):454-7
12350483
J Clin Oncol. 1999 Jan;17(1):168-72
10458230
Urology. 1998 May;51(5):759-64
9610589
BJU Int. 2008 Jul;102(1):24-7
18341623
Cancer. 1996 Sep 1;78(5):1079-84
8780546
BJU Int. 2010 Mar;105(6):818-23
19751264
J Clin Oncol. 2000 Mar;18(6):1164-72
10715284
Urology. 2007 Jun;69(6):1095-101
17572194
J Urol. 2004 Jun;171(6 Pt 1):2260-4
15126798
Am J Surg Pathol. 2003 Apr;27(4):432-40
12657927
Eur Urol. 2007 Sep;52(3):733-43
17350750
J Urol. 1996 Apr;155(4):1344-7
8632570
Eur Urol. 1999;36(1):21-30
10364651
J Urol. 2004 Jun;171(6 Pt 1):2209-14
15126787
Urology. 2003 Apr;61(4):742-7
12670558
Urology. 2002 Dec;60(6):1034-9
12475665
Br J Cancer. 2006 Nov 6;95(9):1186-94
17077805
J Urol. 1996 Oct;156(4):1375-80
8808875
J Urol. 1996 Sep;156(3):1059-63
8709307
Eur Urol. 2000 Apr;37(4):449-55
10765076
J Urol. 2003 Jun;169(6):2136-41
12771735
Urology. 1998 Dec;52(6):1079-84
9836558
Eur Urol. 2008 Oct;54(4):728-39
18603352
J Urol. 1998 Jun;159(6):2023-9
9598511
Urology. 2002 May;59(5):704-8
11992844
J Urol. 2009 Apr;181(4):1628-33; discussion 1633-4
19233388
Rev Urol. 2003;5 Suppl 3:S3-S13
16985948
Urology. 2008 Oct;72(4):887-91
18329080
Cancer. 1995 Jan 15;75(2):530-8
7529129
Urol Oncol. 2003 May-Jun;21(3):213-8
12810209
J Urol. 1996 Apr;155(4):1361-7
8632575
Eur Urol. 2009 Dec;56(6):891-8
19683860
JAMA. 1994 Feb 2;271(5):368-74
7506797
Urol Int. 2006;77(3):200-4
17033205
Urology. 1994 Sep;44(3):371-6
7521093
Scand J Urol Nephrol. 2009;43(2):109-13
19242861
Cancer. 1997 Nov 1;80(9):1852-6
9351559
Histopathology. 2008 Aug;53(2):177-83
18752501
BJU Int. 2008 Apr;101(7):809-16
18321314
Urology. 2000 Apr;55(4):572-7
10736506
Cancer. 2008 Oct 15;113(8):2068-72
18792067
Am J Surg Pathol. 2005 Sep;29(9):1228-42
16096414
Urology. 1999 Oct;54(4):689-93
10510929